Arbutus Biopharma Corp. buy Maxi_Scalibusa
Start price
01.12.21
/
0%
€4.85
Target price
01.12.22
-
Performance (%)
-53.67%
End price
02.12.22
€2.25
Summary
This prediction ended on 02.12.22 with a price of €2.25. The BUY prediction by Maxi_Scalibusa for Arbutus Biopharma Corp. performed very badly with a performance of -53.67%. This prediction was marked as speculative and is excluded from Maxi_Scalibusa's performance statistics.Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Arbutus Biopharma Corp. | -0.156% | -0.156% | 13.113% |
iShares Core DAX® | -1.370% | -3.231% | 11.661% |
iShares Nasdaq 100 | 0.172% | -3.339% | 36.491% |
iShares Nikkei 225® | -0.801% | -7.859% | 18.597% |
iShares S&P 500 | -0.369% | -2.979% | 26.341% |
According to Maxi_Scalibusa what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Cons
Comments by Maxi_Scalibusa for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Buy Arbutus Biopharma Corp.
In the thread Trading Arbutus Biopharma Corp.
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Maxi_Scalibusa for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.45
16.11.20
16.11.20
-
16.11.21
16.11.21
-14.81%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model